Skip to content

Catalyst Biosciences

Primary Menu

About
Pipeline
Science
- Overview
- Publications
Clinical Trials
Investors
Careers
Contact

Investors

Press Releases

Keyword Search

Year

May 9, 2022

Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results

March 31, 2022

Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update

March 15, 2022

Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in Ophthalmology

February 17, 2022

Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives

January 25, 2022

Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency

Overview
Press Releases
Events and Presentations
Financials & Filings
Stock Information
- Stock Quote
- Stock Chart
Corporate Governance
Investor FAQ

Shareholder Tools

Print Page
RSS Feeds
Email Alerts

About
Pipeline
Science
- Overview
- Publications
Clinical Trials
Investors
Careers
Contact

Catalyst Biosciences

Catalyst Biosciences
| 611 Gateway Blvd., Suite 710,
South San Francisco, CA 94080

© Catalyst Biosciences. All rights reserved.
Terms of Use Privacy Policy Cookie Notice

Twitter
LinkedIn
Facebook